- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Onivyde Approved for Advanced Pancreatic Cancer
Patients with metastatic pancreatic cancer who have progressed on gemcitabine now have the option of Onivyde combined with leucovorin/fluorouracil.
Pancreatic cancer patients who have progressed on the standard of care gemcitabine now have another option. The FDA today approved Onivyde (irinotecan liposome) in combination with fluorouracil and leucovorin for this patient population.
Pancreatic cancer sees a very high mortality rate because the disease is diagnosed late, when the patient is at an advanced stage, due to alck of symptoms.
Onivyde was granted both Priority Review and orphan drug designation by the regulatory authority. In a 3-arm, randomized, open-label study with 417 patients with metastatic pancreatic adenocarcinoma, who had relapsed on a gemcitabine-based regimen. The study evaluated whether Onivyde plus leucovorin/fluorouracil or Onivyde alone improved survival than when patients were treated with leucovorin/fluorouracil alone. Including Onivyde in the regimen improved patient survival by about 2 months, the trial showed.
Read the FDA press release here.
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Prediagnosis Diet Improves Survival in Black Women With Deadly Ovarian Cancer
October 24th 2024Moderate prediagnosis adherence to dietary guidelines was associated with improved survival rates among Black women with high-grade serous ovarian cancer, the most common and lethal type of ovarian cancer.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Rozanolixizumab Effective in Patients with MuSK MG, Analysis Shows
October 23rd 2024A new subgroup analysis of patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive (Ab+) myasthenia gravis (MG) shows rozanolixizumab (Rystiggo) contributes to meaningful symptom improvement.
Read More
